Abstract: The present invention relates to a method for assessing Atenolol with precision. A pharmaceutical composition comprising: a predefined amount of Atenolol or pharmaceutically acceptable salts thereof; and a combination of pharmaceutical excipients suitable for oral administration, wherein the method for tailoring the treatment of hypertension comprises of determining the levels of C-reactive protein, blood pressure, blood urea, and HbA1c in hypertensive patients; stratifying patients into distinct subgroups based on the identified biomarker levels; and customizing antihypertensive treatment plans for each subgroup, wherein treatment may include, but is not limited to, beta blockers such as Atenolol.

Abstract: Methods and systems are disclosed, including a method for confining an annihilation range of a positron, from a plurality of positrons emitted from an object being imaged in a positron emission tomography (PET) imaging system. Confining the annihilation includes applying a stochastic multidimensional time varying magnetic field on the positron. Optionally, the stochastic multidimensional time varying magnetic field includes components in each of three dimensions.

Abstract: Methods and systems are disclosed, including a method for confining an annihilation range of a positron, from a plurality of positrons emitted from an object being imaged in a positron emission tomography (PET) imaging system. Confining the annihilation includes applying a stochastic multidimensional time varying magnetic field on the positron. Optionally, the stochastic multidimensional time varying magnetic field includes components in each of three dimensions.